Citigroup Inc Standard Biotools Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Standard Biotools Inc. stock. As of the latest transaction made, Citigroup Inc holds 247,855 shares of LAB stock, worth $314,775. This represents 0.0% of its overall portfolio holdings.
Number of Shares
247,855
Previous 230,625
7.47%
Holding current value
$314,775
Previous $445,000
2.7%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding LAB
# of Institutions
144Shares Held
274MCall Options Held
6.7KPut Options Held
48.7K-
Casdin Capital, LLC New York, NY71.3MShares$90.5 Million10.73% of portfolio
-
Viking Global Investors LP58.7MShares$74.5 Million0.35% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$27.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.2MShares$21.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY16.9MShares$21.4 Million0.0% of portfolio
About STANDARD BIOTOOLS INC.
- Ticker LAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 78,654,800
- Market Cap $99.9M
- Description
- Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...